香港股市 已收市

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
971.91-13.11 (-1.33%)
市場開市。 截至 11:47AM EDT。

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

版塊Healthcare
行業Biotechnology
全職員工13,677

高階主管

名稱頭銜支付行使價出生年份
Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, CEO & Co-Chairman8.18M1953
Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman7.76M1960
Dr. Andrew J. Murphy Ph.D.Executive Vice President of Research1.68M21.37M1959
Mr. Daniel P. Van PlewExecutive VP and GM of Industrial Operations & Product Supply2.01M10.67M1973
Mr. Christopher R. Fenimore CPASenior VP of Finance & CFO1971
Ms. Patrice GiloolySenior Vice President of Quality Assurance & Operations
Mr. Bob McCowanSenior VP of IT & Chief Information Officer
Mr. Ryan CroweSenior Vice President of Investor Relations & Strategic Analysis
Mr. Joseph J. LaRosaExecutive VP, General Counsel & Secretary1.75M23.23M1959
Ms. Melissa LoznerSenior VP & Chief Compliance Officer
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

公司管治

截至 2024年5月1日 止,Regeneron Pharmaceuticals, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中:10;董事會:10;股東權利:10;現金賠償:9。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。